Boston Scientific Corporation (BSX) – What Are Brokerages Saying About This Stock?

Posted by George Bondi on Oct 30th, 2026

Boston Scientific logo Boston Scientific Corporation (NYSE:BSX – Get Free Report) has been given an average rating of “Moderate Buy” by the thirty-one research firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation, twenty-one have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $61.87.

BSX has been the topic of several research reports. Rothschild & Co Redburn cut their target price on Boston Scientific from $106.00 to $78.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Stifel Nicolaus decreased their price target on shares of Boston Scientific from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Monday. Raymond James Financial reiterated an “outperform” rating and issued a $57.00 price objective (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. Canaccord Genuity Group cut their price objective on shares of Boston Scientific from $66.00 to $48.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Deutsche Bank Aktiengesellschaft set a $48.00 target price on shares of Boston Scientific in a report on Thursday.

View Our Latest Report on Boston Scientific

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael Mahoney acquired 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director David Habiger acquired 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have bought 189,522 shares of company stock valued at $9,157,810. Company insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Perigon Wealth Management LLC bought a new position in shares of Boston Scientific in the 2nd quarter valued at about $883,000. Y Intercept Hong Kong Ltd raised its holdings in shares of Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after purchasing an additional 670,060 shares during the period. Wealthfront Advisers LLC bought a new stake in shares of Boston Scientific in the 2nd quarter valued at about $3,253,000. PensionDanmark Pensionsforsikringsaktieselskab raised its holdings in shares of Boston Scientific by 9.9% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after purchasing an additional 28,961 shares during the period. Finally, Tocqueville Asset Management L.P. acquired a new stake in Boston Scientific in the 2nd quarter valued at about $38,539,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: Third-quarter revenue increased 1.5% year over year to $5.138 billion, topping the $5.07 billion consensus estimate, while adjusted earnings of $0.73 per share matched expectations. Boston Scientific announces results for third quarter 2026
Positive Sentiment: Robert W. Baird raised its price target from $50 to $51 and maintained an “outperform” rating, while BTIG, UBS and Sanford C. Bernstein retained bullish ratings despite lowering their targets. Analysts revise forecasts after Q3 results
Positive Sentiment: Management pointed to long-term growth initiatives, including Elite AF trial enrollment and FDA clearances for StoneSmart and SEISMIQ catheter technologies. Recent insider activity also showed purchases rather than sales, offering a modest confidence signal.
Neutral Sentiment: Boston Scientific expects approximately 4.25% reported full-year 2026 sales growth, but forecast fourth-quarter reported and organic sales declines of 1% to 3%. Boston Scientific cuts view again after cyberattack
Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by roughly $150 million and continues to affect operations, customer activity and the recovery timeline.
Negative Sentiment: Management lowered full-year adjusted EPS guidance to $3.16-$3.18, below investor expectations, and warned that growth could remain broadly flat in 2027 as EP and WATCHMAN weakness, China pricing pressure and product-related challenges persist. BSX Q3 earnings call flags growth challenges
Negative Sentiment: Analyst sentiment became more cautious: Oppenheimer downgraded BSX to “market perform,” JPMorgan moved to “neutral,” and multiple firms cut price targets, including Wells Fargo to $45 and Needham to $48.

Boston Scientific Stock Performance

BSX opened at $42.69 on Friday. The company has a market capitalization of $61.86 billion, a price-to-earnings ratio of 18.09, a P/E/G ratio of 1.04 and a beta of 0.58. The business’s 50-day moving average price is $44.93 and its two-hundred day moving average price is $57.15. Boston Scientific has a 1 year low of $39.57 and a 1 year high of $105.65. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting the consensus estimate of $0.73. The company had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. Boston Scientific had a return on equity of 18.73% and a net margin of 16.62%. Boston Scientific’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.75 earnings per share. Equities analysts expect that Boston Scientific will post 3.18 EPS for the current fiscal year.

Boston Scientific Company Profile

(Get Free Report)

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.